Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

KineMed Announces Agreement With MedImmune

Published: Wednesday, May 22, 2013
Last Updated: Wednesday, May 22, 2013
Bookmark and Share
Research will utilize Kinemed technology to study protein dynamics related to neurodegenerative diseases.

KineMed Inc. announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to study how a monoclonal antibody affects the dynamics of the cellular prion protein (PrPc).

Cellular prion protein is found in healthy people, but this protein is known to have altered conformation and function in several neurodegenerative conditions including Creutzfeldt–Jakob disease and fatal familial insomnia. Recent research has also demonstrated that the prion protein may be a key component of Alzheimer's disease. KineMed’s platform technology will allow MedImmune to track the prion protein, providing insight into how an antibody directed at PrPc will affect the turnover and expression of the protein at the cell surface.

“We are very pleased to work with MedImmune in the search for new and effective treatments for neurodegenerative diseases,” said Dr. Ravi Kiron, Chief Business Officer of KineMed. “The growing toll of neurodegenerative disease in the aging global population is an enormous burden for patients, healthcare providers, and healthcare systems world-wide. KineMed is committed to partnering with innovative biotech companies like MedImmune to help accelerate the discovery and approval of new and effective therapies for neurodegenerative disease.”

The MedImmune scientists working on this project are part of the AstraZeneca Neuroscience Innovative Medicines Unit.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!